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Abstract
Introduction—The correlation between monofilament testing, symptom surveys and
electrodiagnostic studies for the diagnosis of axonal polyneuropathy has not been well studied.
This study was to assess the agreement between these procedures in a non-random sample of
volunteers.
Methods—The evaluated procedures included electrodiagnostic tests of the sural nerve,
monofilament testing of the great toe, a symptom survey and a body diagram. Kappa coefficients,
sensitivity and specificity, using nerve conduction as a ‘gold standard’, were used to determine the
agreement between various combinations of procedures.
Results—Poor agreement (Kappa values: −0.12 ~ 0.44) and sensitivity (sensitivity<30%) were
found for all combinations of symptoms and monofilament results in comparison with sural peak
latency and amplitude.
Discussion—Overall, the results demonstrated a low discriminatory power for the screening
procedures for identifying persons with impaired sural nerve function. The results highlight the
need for further development and evaluation of screening methods for distal neuropathy in
population-based studies.
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1. Introduction
Peripheral neuropathy in the lower extremity is clinically important in the general
population. Polyneuropathy can have a variety of causes, including exposure to toxins,
metabolic disorders, or infection. The detection of mild peripheral neuropathy may require
careful clinical examination and/or the use of electrodiagnostic testing. The American
Academy of Neurology and others have offered consensus definitions of polyneuropathy 1.
*Corresponding author: Alfred Franzblau, M.D., M1835 SPH I, 1415 Washington Heights, University of Michigan School of Public
Health, Ann Arbor, MI 48109-2029, USA, afranz@umich.edu, Office: +1 (734)936-0758 Fax: +1 (734)763-7105.
The authors declare that they have no competing financial interests.
NIH Public Access
Author Manuscript
Muscle Nerve. Author manuscript; available in PMC 2013 May 01.
Published in final edited form as:
Muscle Nerve. 2012 May ; 45(5): 653–658. doi:10.1002/mus.23238.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Quick and accurate screening and clinical diagnosis rely on high sensitivity and specificity
of the methods employed. The sensitivity and specificity of the techniques employed
significantly affect the outcomes of clinical screening and are also important for
epidemiological research of peripheral neuropathy in the lower extremity.
Several tools and procedures such as electrodiagnostic testing, quantitative sensory tests,
physical examination procedures, body diagrams and symptom questionnaires have been
employed for screening and epidemiological research of peripheral neuropathy. Each of
these tools and procedures has strengths and weaknesses. Both electrodiagnostic testing and
quantitative vibratory quantitative sensory tests are highly reproducible and complementary
to each other 2–4. However, the role of quantitative vibratory tests in diagnosis of distal
neuropathy needs to be studied further 1. The advantage of electrodiagnostic testing is that it
provides an objective measure of peripheral nerve function, which clinical psychophysical
examinations do not offer. Therefore, to detect peripheral neuropathy in the lower
extremities, sural nerve conduction testing is considered to be an appropriate tool 5.
However, electrodiagnostic testing requires specific equipment and training for examiners.
The objective of this study was to assess the agreement between electrodiagnostic testing,
monofilament testing, a lower extremity symptom survey and a body diagram in
identification of possible peripheral neuropathy in the feet. The analysis for the assessment
was carried out in a population of dental professionals.
2. Materials and Methods
Subjects were recruited during the Michigan Dental Association (MDA) annual conventions
held in 2009 (n=232) and 2010 (n=283). They represented a convenience sample of dental
professionals who attended the conventions and were recruited for a gene-environment study
that investigated the relationship of nerve conduction tests with urinary and hair mercury
biomarkers in dental professionals. Each participant signed a written informed consent
approved by the University of Michigan Institutional Review Board (HUM00027621).
2.1 Electrodiagnostic Testing
Nerve conduction tests performed included amplitude, onset latency and peak latency of the
sural nerve in the right ankle. We chose to only present results based on amplitude and peak
latency, and not onset latency. The latter is highly correlated with peak latency, and
measurement of peak latency tends to have better reliability than onset latency 4. A TECA
Synergy (Oxford Instrument, Hawthorne, NY) was used to record the amplitude and peak
latency after stimulation was applied on the posterior aspect of the right calf, 14cm proximal
to the standard recording electrode placed behind the lateral malleolus in the lower
extremity. The temperature of the right midfoot was recorded at the time of measurement.
Feet were warmed with electric heating pads if the limb temperature was initially below 32
°C. The peak latency (milliseconds-ms) was defined as the time required for an electrical
stimulus to reach peak deflection from baseline of an action potential waveform. The
amplitude (microvolts-μV) was defined as the baseline-to-peak voltage difference of the
waveform. We took the best supramaximal stimulation of several trials for our amplitude
measurements. All parameters were recorded in accordance with the guidelines outlined by
the American Association of Electrodiagnostic Medicine 6.
2.2 Self-administrated Symptom Questionnaire and Body Diagram
Each subject completed a self-administered questionnaire to collect information on
demographics and current symptoms of the lower extremities along with pre-existing
diseases. If subjects reported any symptoms in their feet in the week prior to the survey, they
were asked to report the duration of time they felt numbness and/or tingling in their feet in
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the following format: < 6 weeks, 6–12 weeks, or > 12 weeks (Sx). Due to small numbers,
the duration of symptoms was excluded from subsequent analyses.
Subjects also completed a self-administrated full-body symptom diagram. They were asked
to shade areas where numbness, tingling, burning or pain had occurred more than three
times, or had lasted more than one week in the previous six months. In this analysis, only
areas at or below the right ankle were reviewed and scored independently by two raters for
symptoms consistent with neuropathy in the feet. Any discrepancies were reconciled
between the two raters through consensus. The results of body diagram symptoms (BDS)
were classified into three categories with respect to symptom distribution consistent with
neuropathy in the feet, including probable, possible, and unlikely (See Appendix for specific
definitions). Symptoms consistent with neuropathy in the feet were defined in different ways
using combinations of the body diagram and symptom questionnaire.
2.3 Monofilament Testing
The plantar surface of the great toe on the right foot was tested for peripheral sensation
using a 5.07-gauge Semmes-Weinstein nylon monofilament (Wound Central, Aurora, IL) 7.
We chose one monofilament instead of all 20 monofilaments in order to simplify the data
collection by minimizing the time spent on each subject and maximizing the sample size of
the study. The 5.07-gauge monofilament has been shown to be the best predictor among all
20 monofilaments to determine the loss of protective sensation in the feet among diabetic
subjects 8. The use of a single monofilament resulted in a single outcome (“positive” or
“negative”). Prior to the test, patients were asked to feel the monofilament on their fingertip.
The monofilament was then applied up to three times to the right great toe with sufficient
force to bend the filament. Patients were asked to indicate when a touch occurred. The test
result was recorded as abnormal if a subject did not indicate a monofilament touch on two
consecutive tries.
3. Statistical Analyses
Abnormal sural nerve function was defined by two separate criteria used by the University
of Michigan Electroneuromyography Laboratory: 1) age-adjusted peak latency >4.1ms (20–
60 years old) or >5ms (>60 years old); 2) age-adjusted amplitude ≤ 6μV (20–60 years old)
or ≤ 5μV (>60 years old). In addition to age adjustment, the corrected peak latency was
defined by adjusting to a standard temperature of 32 °C based on the following formula:
latency corrected=latency initial− 0.3msec*(32°C-temperature in °C) 9. No temperature
adjustment was applied to amplitudes, because in our data temperature was not a predictor
of the sural amplitude in multivariate linear regression analysis (not shown). Due to missing
values (n=56) for foot temperature, the sample size for peak latency was smaller than that
for amplitude.
Since nerve conduction and monofilament tests were conducted only on the right foot, all
analyses describe results only in the right foot. All analyses were performed using SAS 9.2
(SAS Institute, Inc. Cary, NC). Agreement of electrodiagnostic findings with symptoms
consistent with neuropathy in the feet and monofilament results, respectively was assessed
by kappa coefficients. Separate kappa coefficients were calculated for all subjects, diabetic
subjects, and non-diabetic subjects. Kappa results were interpreted as excellent (>0.75), fair
to good (0.40~0.75) and poor (<0.40) 10. Pearson chi-square tests or Fisher exact tests were
performed to assess the association of electrodiagnostic findings with symptoms consistent
with neuropathy in the feet and monofilament results. Using sural nerve function (peak
latency and/or amplitude) as the gold standard, sensitivity and specificity of various
combinations of the other tests (body diagram, symptom questionnaire, and monofilament)
were calculated. To reflect the clinical relevance of the nerve function as continuous
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measurements, we also calculated the mean nerve function stratified by various
combinations of the clinical tests discussed above. Normality tests showed the distributions
were not normal for temperature- and age-adjusted peak latency (Shapiro-Wilk = 0.98;
p<0.0001) and amplitude (Shapiro-Wilk = 0.94; p<0.0001). The mean amplitude and
corrected peak latency were compared between test strata using non-parametric Mann-
Whitney tests.
4. Results
The prevalence of self-reported diabetes was approximately 4% (Table 1). Diabetic subjects
were significantly older and had higher BMI than non-diabetic subjects. The proportions of
positive findings for the various symptom criteria (Table 2) are shown in Table 3. Except for
peak latency, the proportions of positive findings in the diabetic subjects were higher than
those in the non-diabetic subjects. In general, the proportion of abnormal nerve function
findings was usually higher than that of abnormal monofilament results.
The main results were summarized in Table 4. Overall, kappa values (−0.12–0.44) were
mostly poor, sensitivity was low, and specificity was high. Monofilament testing appeared to
perform slightly better than symptom surveys among non-diabetic subjects. Not
surprisingly, results among diabetic subjects were somewhat better than among non-diabetic
subjects. However, the number of diabetic subjects was small, so the confidence intervals
tend to be broad, and none of the results achieved statistical significance. Chi-square test
statistics and p-values showed that significant associations in all subjects occurred only in
those combinations whose kappa values were among the highest. In Supplemental Tables 1–
3, we also showed kappa values, sensitivity and specificity for the combinations of
monofilament findings and symptom results in comparison with abnormal amplitude or peak
latency, abnormal peak latency alone, or abnormal amplitude alone, respectively. We
observed similar patterns in the low kappa coefficients, high sensitivity and low specificity.
Comparisons of means of nerve function between screening test strata were performed using
Mann-Whitney tests (See Supplemental Tables 4–5). Given the small numbers, none of the
means differed significantly for either sural amplitude or peak latency among diabetic
subjects. Results for all subjects and for non-diabetic subjects were similar. The means of
peak latency did not differ significantly for any screening outcome defined purely on the
basis of the body diagram with or without symptoms. In contrast, the comparison of mean
amplitudes differed significantly in the expected direction for the body diagram and for most
combinations of the body diagram with symptoms. The mean peak latency among all
subjects with a positive monofilament test (mean = 4.13 ms) was significantly greater than
among those with a negative monofilament test (mean = 3.51 ms; p = 0.05). Consistent with
the latency results, the mean amplitude among all subjects with a positive monofilament test
(mean=6.71 uV) was significantly lower than among those with a negative monofilament
test (mean=13.12 uV; p < 0.0001). Despite these differences, the overlap of the distributions
of nerve test results when stratified by screening test outcome was considerable (See
Supplemental Figures 1a–2b).
5. Discussion
We assessed the agreement between electrodiagnostic testing results (sural nerve peak
latency and amplitude), monofilament findings and symptoms consistent with neuropathy in
the right foot of a non-random convenience sample of dental professionals. Overall, the low
kappa coefficients showed poor agreement between electrodiagnostic tests and the other
procedures. Kappa coefficients in diabetic subjects were somewhat higher than in non-
diabetic subjects.
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Using nerve conduction as the gold standard, the sensitivity and specificity of various
combinations of the screening tests were mostly low and high, respectively. The results of
mean differences in nerve function (See Supplemental Tables 4–5) revealed some significant
differences, but the clinical utility of these differences may be limited by the observed
considerable overlap of the distributions of ‘normal’ and ‘abnormal’ screening results. These
results highlighted the potential influence of nerve function cutoff values and the potential
importance of using nerve function as a continuous versus dichotomous outcome in
comparing test procedures. Unlike some other clinical procedures that produce binary
outcomes, nerve conduction is measured on a continuum. Peripheral neuropathy, defined by
measured nerve function, is therefore a continuum. This might have had an impact on the
results of poor agreement between the screening procedures, although the direction of such
an impact was not clear. However, as was shown in Supplemental Figure 1, there was
considerable overlap of the distributions of nerve conduction parameters among those with
normal and abnormal screening test results based on monofilaments, body diagrams, or
symptoms.
The study examined the agreement between different screening tools and procedures for
neuropathy in the lower extremity in a non-random convenience sample of volunteers. A
similar study that investigated such agreement in the upper extremity also reported relatively
poor agreement between physical examinations, electrodiagnostic findings and symptoms
consistent with carpal tunnel syndrome 11. The results of the present study point to a need
for further development and evaluation of the methods used to screen for neuropathy in the
feet. The low prevalence of positive findings highlighted the challenge of developing a
screening tool for peripheral neuropathy for use in non-clinical populations, because positive
predictive value and negative predictive value are a function of prevalence, and not just
sensitivity and specificity. Overall, the results demonstrated a low discriminatory power
between the screening procedures for identifying persons with impaired sural nerve function
in a non-random convenience sample of volunteers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix
The criteria for defining neuropathy in the feet:
2 Probable
• If both feet are entirely shaded
• If a large portion of both feet, including all toes, is shaded
• If all toes are shaded in both feet
1 Possible
• If shaded areas include one or more but not all of the toes
• If shaded areas include anywhere in the foot but not toes
• If shaded areas include anywhere in the foot including toes
• If one foot is fully shaded but the other foot has only partial shading
0 Unlikely
• If no shading anywhere on feet below ankle
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• If other non-lateral parts of foot are shaded; toes are not shaded
• No shading anywhere on toes regardless of shading elsewhere
• Shading present on only one foot
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Table 2
Neuropathy Definitions from Results of Body Diagram Scores and Symptom Questionnaire
Symptom Consistent with Neuropathy Abbreviation Definition
Definition a: Body diagram score BDS Probable or possible body diagram score for neuropathy
Definition b: Body diagram score & numbness and/or
tingling in feet
BDS & Sx Probable or possible body diagram score for neuropathy and
numbness and/or tingling in feet
Definition c: Body diagram score or numbness and/or
tingling in feet
BDS or Sx Probable or possible body diagram score for neuropathy or
numbness and/or tingling in feet
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